Summit Therapeutics to Participate in Upcoming Investor Conferences

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that management will participate in two upcoming investor conferences in New York City, US.

• 29th Annual Piper Jaffray Healthcare Conference – November 28, fireside chat at 1:30pm EST
• Oppenheimer Rare Disease Day – December 5

A live audio webcast of the Piper Jaffray fireside chat will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. For the Oppenheimer Rare Disease Day, the Company will participate in one on one meetings.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker)	Tel:	[phone]
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
MacDougall Biomedical Communications (US)	Tel:	[phone]
Karen Sharma		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Sue Stuart /		[e-mail]
Jessica Hodgson / Philippa Gardner

-END-